chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache & Arthralgia Narrative:  g. Symptoms/Complaints - Worsening headache, arthralgia (in hands primarily) unable to work today 1/14
drooping face; loss of appetite; shortness of breath; rapid pulse; cold sweat; slightly feverish; fatigue; severe joint pain; slept for 13 hours; calves and thighs hurt for 4 day; This spontaneous case was reported by a consumer and describes the occurrence of FACIAL PARALYSIS (drooping face) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007321A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No relevant medical history reported).   On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Mar-2021, the patient experienced HYPERSOMNIA (slept for 13 hours) and PAIN IN EXTREMITY (calves and thighs hurt for 4 day). On 20-Mar-2021 at 4:00 PM, the patient experienced FACIAL PARALYSIS (drooping face) (seriousness criterion medically significant), DECREASED APPETITE (loss of appetite), DYSPNOEA (shortness of breath), HEART RATE INCREASED (rapid pulse), COLD SWEAT (cold sweat), PYREXIA (slightly feverish), FATIGUE (fatigue) and ARTHRALGIA (severe joint pain). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 21-Mar-2021, FACIAL PARALYSIS (drooping face), DECREASED APPETITE (loss of appetite), DYSPNOEA (shortness of breath), HEART RATE INCREASED (rapid pulse), COLD SWEAT (cold sweat), HYPERSOMNIA (slept for 13 hours), PYREXIA (slightly feverish), FATIGUE (fatigue) and ARTHRALGIA (severe joint pain) had resolved. On 24-Mar-2021, PAIN IN EXTREMITY (calves and thighs hurt for 4 day) had resolved.       No concomitant medications were reported.  Treatment included ibuprofen for the event PAIN IN EXTREMITY (calves and thighs hurt for 4 day).   This case was linked to MOD-2021-074831 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
One week following the first dose, a big red circle (about five inches across) developed at the site of the injection. It was very itchy.
Seizure <1 hr after receiving HBV #3 and 1st flu vaccine.
PAROSMIA; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the subject experienced parosmia. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of parosmia was not reported. This report was non-serious.
Pfizer COVID vaccine #3 given 8/25/21, lot # FC3184; 1/12/22 pt went to dr's office with productive cough, negative COVID test, CXR showed pneumonia; treated with steroids, and ABX and sent home; later in the week, he developed chills and hypoxia (on 4L O2 via NC and O2 sats in 70s);  1/24/22 brought to ED via EMS and admitted; positive COVID test; increased O2 to 15 L; given remdesivir, ABX, and dexamethasone; increased O2 demands requiring ventilator; developed acute thromobosis; condition worsened; Atrial flutter; tracheostomy performed; G tube placed; continued encephalopathy; wife made pt a DNR but not to withdraw care; 3/5/22 pt transferred to Hospital where he passed away
Resident ordered Hib for 19 y/o patient, patient given Hib.
Arm pain, fever, chills, sweats, fatigue. Loss of ability to complete normal activities for 24 hrs
Information has been received from a physician concerning a male who was vaccinated with varicella virus vaccine live (Oka/Merck). The patient experienced a varicella-like rash with approximately 35 lesions after receiving the varicella virus vaccine live (Oka/Merck). Unspecified medical attention was sought. No product quality complaint was involved. Additional information is not expected.
Coordinator is responsible for filling syringes with Moderna vaccine for mass injection sites. A few syringes with retractable needle were aspirated/being prepared for drawing up vaccines from multi dose vial of Moderna Booster. They got mixed up with  the vaccines that already were filled with a dose of Moderna. RN administered one on patient  at 8:34am. Upon doing so she noticed that it felt very "Airy". She then let me know of the empty syringes and I removed them. I prepare 20 vaccines at a time and place 10 at a time to administer so only the one was missing. Provider spoke to patient and asked if he was feeling any symptoms like he felt when he first got the two first full doses. He states he was not having those symptoms, provider recommended he come back in two weeks and we can administer the booster again.  No other symptoms or physical complaints from patient.
I woke up in the middle of the night with a headache and body aches. I got up to take ibuprofen and when I was in my bathroom, I collapsed. I do not remember actually falling but I heard the thud when I hit the floor. I tried to get up and had absolutely no strength in any part of body.  My husband came to help me up but I could not even lift up my head. He was finally able to help me up and I took a few steps and collapsed/fainted again. This has never happened to me in my life.
Patient received expired Moderna Covid-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received expired Moderna Covid-19 vaccine) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     Concomitant products included HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL/HCTZ) for Hypertension.   On 18-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received expired Moderna Covid-19 vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received expired Moderna Covid-19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Follow up information received on 22-Jun-2021 and included concomitant medication details were added, Suspect vaccine (2nd dose) route of administration was updated.
(R) arm 8 x 12 cm red, hot induration itching - local reaction. No anaphylaxis. No generalized reaction.
Elevated temperature, Excruciating arm, shoulder armpit and left breast pain upon exertion. Pain subsided within minutes upon resting.
pt vax hepta B.  3 or 4 days later pt devel. hives and at the end of jan or beg. of feb 1990 pt devel. erythmema multiforme.
My right arm still has a red welt on it and it' 2/9.; This is a spontaneous report from a contactable consumer (patient). A 42-years-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: En5318), via an unspecified route of administration on 30Jan2021 16:45 as SINGLE DOSE (at the age of 42-years) in Arm Right for covid-19 immunization. The patient was not pregnant at the time of vaccination. The patient medical history and concomitant medications were not reported. The patient did not receive other vaccines four weeks prior to COVID vaccination. The patient did not receive other medications two weeks prior to COVID vaccination. Prior to the vaccination the patient was not diagnosed with COVID-19. On 30Jan2021, the patient's right arm still has a red welt on it and it' 2/9. The patient did not receive treatment for the event. Since the vaccination the patient had not been tested for COVID-19. The outcome of the event was recovered with sequelae on an unspecified date in 2021 (recovered with lasting effects).
Left upper arm erythema, slight swelling with warm to touch started yesterday afternoon. MD gave Cefzil 250mg BID, Benadryl 12.5 25mg at 10prn and warm compresses.
Patient came to office for complaints of body aches, chills, hot flashes, sweating and lightheaded. Nausea and loss of appetite.
sick for 2 days; Initial information was received on 08-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via the social media .  This case involves a patient (unknown age) who was sick for 2 days (illness), while he/she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), concomitant therapy, vaccination(s) and family history were not provided.  On an unknown date, the patient received first and second dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was sick for 2 days (illness) (Unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.  There will be no information available on batch number for this case.
Onset 6/18/06 low-grade temp (100), lethargy, nausea. 6/19/06-6/20/06-To ER, Re-hydrated, given K+ tablets, continued low-grade temp, nausea. Rash developed on 6/22/06. To ER for re-hydration after seen by MD; To MD (Dermatologist) for biopsy of back lesion 6/26/06. MD confirmed DX: "chickenpox". To see MD on 6/29/06 for follow-up. Recovering per mother 6/28/06.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 45 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 26Aug2021 12:00 (Lot number: EW0181) at the age of 45 years as dose 2, single for Covid-19 immunisation. Relevant medical history included: "Neurofibromatosis" (ongoing), notes: Verbatim: Neurofibromatosis, type 1 (von Recklinghausen's disease). Diagnosed at 36 years old. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, COVID-19 Vaccine:, Date: 03Aug2021, Time: 11AM, LOT: EW0182, Injection in the right arm), administration date: 03Aug2021, when the patient was 45 years old, for COVID-19 Immunisation, reaction(s): "First dose, experienced a dead arm in the injection arm, which was the right arm", "Couldn't lift arm". The following information was reported: PYREXIA (non-serious) with onset 26Aug2021, outcome "recovered" (2021), described as "Fever"; NAUSEA (non-serious) with onset 26Aug2021, outcome "recovered" (2021), described as "Sick to stomach"; ASTHENIA (non-serious) with onset 27Aug2021, outcome "recovered" (2021), described as "Felt puny and weak". Relevant laboratory tests and procedures are available in the appropriate section. Additional information included: After receiving first dose, patient experienced a dead arm in the injection arm, which was the right arm. Couldn't lift arm because it hurt. Felt like was punched in the arm. Was continuous. Lasted only for a few hours and passed. Recovered completely. After reviewing the call recording it was confirmed that the caller stated they all three got the shot on the same dates, the first dose on 03Aug2021 and second shot on 26Aug2021. This was captured as provided by the caller. Also, it was stated the reporter that she and the 20-year-old son had the same experience after the first dose, the dead arm feeling, and therefore the event was captured and confirmed by the call handler for both reports. This information was captured accurately by the call handler. No follow-up attempts are possible. No further information is expected.
11/29/21 presenting today for COVID COMM TESTING (Covid test, positive home test, headache, congestion, cough, bodyaches) and Covid-19 Positive  States has been exposed to Covid.  States husband and son have tested positive.  States has been feeling ill for 3 weeks.  States has had sinus symptoms-nasal congestion and sinus drainage.  States yesterday began feeling more ill with fever up to 103, chills, body aches, headache and cough.  Some shortness of air with exertion.  No chest pain, wheezing.  No abdominal pain, vomiting or diarrhea.  Feeling nauseated Review of Symptoms:   Review of Systems  Constitutional: Positive for chills, fatigue and fever.  HENT: Positive for congestion, postnasal drip,
First shot: tired, low grade fever Second shot: I bled from vaccine immediately and had blood running down my arm before he could put the bandaid on. I woke up the next day with a big bruise at vaccine site
My son received the HPV vaccination and a little while after he started getting a fever, chills, muscle aches.
The CDC changed the correct Moderna vial, 3 weeks after the State changed to all patients get Bivalent COVID vaccines. The correct vials were not available or available to order, at the time the State implemented this change.
received vaccine 1600 and then developed hive like rash on anterior neck only which has continued and patient will be evaluated today 12/24/2020. She did not develop any other allergic reaction symptoms and only other symptom is mild soreness to her arm where she received the vaccine.
No additional AEs reported; one dose of improperly stored MMR II was administered to a patient on 24May2022; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. Information about patient's pertinent medical history, concomitant medications, concurrent conditions and drug reactions/ allergies was not provided.  On 24-MAY-2022, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (recombinant human albumin, rHA) (M-M-R II), lot number: U007686, expiration date: 09-MAR-2023 (dose, dose number and route of administration was not provided) for prophylaxis (product storage error). No additional adverse events (AEs) were reported (no adverse event). No product quality complaint (PQC).  The administered dose of the vaccine experienced a temperature excursion of 13.4 degrees Celsius for 8 hours. There were no previous reported temperature excursions. It was unknown if a digital data logger was involved.
pt recvd vax & had fever to 101 & brief (>1 min generalized sz); taken to ER CBC, blood cx, CXR done all OK; x/for HgB 10.1;
1st Dose on 15-Jan-2021 & 2nd Dose on 27-Feb-2021; Maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st Dose on 15-Jan-2021 & 2nd Dose on 27-Feb-2021) and MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. Last menstrual period and estimated date of delivery were not provided. On 15-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st Dose on 15-Jan-2021 & 2nd Dose on 27-Feb-2021). On 15-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st Dose on 15-Jan-2021 & 2nd Dose on 27-Feb-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment medication was reported.  Company Comment: This is a spontaneous case concerning  a  57-year-old, female patient with no reported medical history, who experienced the unexpected non-serious events of Inappropriate schedule of product administration, Maternal exposure during pregnancy. The event Maternal exposure during pregnancy occurred on the same day after the first dose of mRNA-1273 COVID 19 Vaccine. While the event Inappropriate schedule of product administration occurred on an unknown date. It was reported that patient received the second dose of mRNA-1273 COVID 19 Vaccine on February 27, 2021. The events were reported as outcome unknown. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.   This case was linked to MOD-2022-574007 (Patient Link).; Sender's Comments: This is a spontaneous case concerning  a  57-year-old, female patient with no reported medical history, who experienced the unexpected non-serious events of Inappropriate schedule of product administration, Maternal exposure during pregnancy. The event Maternal exposure during pregnancy occurred on the same day after the first dose of mRNA-1273 COVID 19 Vaccine. While the event Inappropriate schedule of product administration occurred on an unknown date. It was reported that patient received the second dose of mRNA-1273 COVID 19 Vaccine on February 27, 2021. The events were reported as outcome unknown. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.
11/24/22 presents to ED for "shortness of breath". PMHx of "COPD, myelodysplastic disease"
received second dose from expired vial; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received second dose from expired vial) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006C21A and 041C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (received second dose from expired vial). On 15-Oct-2021, EXPIRED PRODUCT ADMINISTERED (received second dose from expired vial) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   no concomitant and treatment medications are provided. The vial was thawed on 24-Sep-2021 and  vial was initially stored in the refrigerator on 24-Sep-2021, vial has not undergone any temperature excursions.
This spontaneous report was received from a pharmacist referring to herself, a female patient of unknown age. The patient's medical history included shingles of the jaw (herpes zoster) on an unspecified date. The patient was not taking concomitant medications. In approximately 2014, reported as about three years ago, the patient received a dose of ZOSTAVAX (dose, route of administration, lot number and expiration date were not provided) for prevention of shingles recurrence. On an unknown date, reported as three months after the ZOSTAVAX administration, the patient developed shingles of the jaw again but "with much less severity". No treatment was given for the adverse event. On an unknown date, the patient recovered from shingles of the jaw, reported as "she only developed a rash and then shortly after it went away on it's own". The causal relationship between the event and ZOSTAVAX was not reported. Additional information is not expected because there was no consent to contact reporter.
Agustin had an allergic reaction and hives and rashes all over his body. The doctor said that the immune system was overreacting to the vaccine. The doctor prescribed Benadryl and he recovered in about 4 days.
Headache; Fatigue; Chills; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), FATIGUE (Fatigue), CHILLS (Chills) and VOMITING (Vomiting) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced HEADACHE (Headache), FATIGUE (Fatigue), CHILLS (Chills) and VOMITING (Vomiting). At the time of the report, HEADACHE (Headache), FATIGUE (Fatigue), CHILLS (Chills) and VOMITING (Vomiting) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  Upon internal review on 21-May-2021, the age was corrected to unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.
Six days after receiving vaccine, began feeling unwell. Symptoms are extreme fatigue, red eyes, sore eyes, body aches, joint pain, pain around back/ribs, shortness of breath on exertion. Unable to do usual household tasks and requiring bedrest for much of the day.   The symptoms are very similar to the waves of symptoms I experienced early on in Post-Acute Covid-19 syndrome. I got sick in March and was experiencing waves like this through November. Since November, my physical symptoms had abated and I had not suffered a major relapse like this, besides a mild relapse at end of January. My shortness of breath issues, back pain/rib pain, eye soreness are very specific symptoms that I associate with early on in my long covid experience. The vaccine seems to have triggered a major relapse in my long covid symptoms.
Localized redness as vaccine site then chest pain and shortness of breath.  Patient transported to the emergency department and then discharged home from ED.
Patient administered vaccine after the manufacture's date of expiration; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine after the manufacture's date of expiration) in a 61-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 08-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine after the manufacture's date of expiration). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine after the manufacture's date of expiration) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  The vial did not undergo any temperature excursions. Date the vial initially stored in the refrigerator was unknown.  Treatment medications were not reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Follow up received non significant information reporter's address updated.